Alterity Therapeutics Ltd., of Melbourne, Australia
Small-molecule inhibitor of alpha-synuclein aggregation
Synucleino-pathies such as Parkinson's disease and multiple system atrophy
Interim data from phase I trial in healthy volunteers showed drug was well-tolerated in 3 multiple-dose cohorts; PBT-434 crosses the blood-brain barrier in humans and achieved concentrations in the brain exceeding those associated with efficacy in animal models of the disease
The date indicated refers to the BioWorld table in which the news item can be found.
For more information about individual companies and/or products, see Cortellis.